LA JOLLA PHARMACE

LA JOLLA PHARMACEUTICAL COMPANY (LJPC)
www.ljpc.com
Prezzo Variazione Volume P/E
16.16 -0.83 €
(-4.89%)
0 -2.25

Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 24
Sell : 20

Andrea Scu Emanuele Nessuno Winston Giuseppe Mariani Antonio Marenna Finalx Tiaril DaniB21B

Commenti

Notizie

This RSS feed URL is deprecated

Leggi

Securities Analyst Recommendations: Apellis Pharmaceuticals, Inc. (APLS), La Jolla Pharmaceutical Company (LJPC) - Analyst Journal

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) tinted gains of +6.87% (+1.07 points) to US$16.65. The volume of 0.17 Million shares climbed down over an trading activity of 245.15 Million shares. EPS ratio determined by looking at last 12 month figures is ... Leggi

Gw Pharmaceuticals Plc (GWPH) Shareholder Scopia Capital Management LP Lowered Its Stake as Stock Value ... - MoneyMakingArticles

Scopia Capital Management Lp who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be less bullish one the $4.61 billion market cap company. The stock decreased 1.87% or $2.72 during the last trading session, reaching ...altro » Leggi

Head to Head Analysis: La Jolla Pharmaceutical (LJPC) and Idera Pharmaceuticals (NASDAQ:IDRA) - Fairfield Current

La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Analyst Recommendations. This is a summary of current ratings and recommmendations ...altro » Leggi

Fibrodysplasia Ossificans Progressiva Drug Market Demand and Supply 2018 to 2025 - Trade Market Research

Top Leading Companies are: AstraZeneca Plc, Blueprint Medicines Corp, Clementia Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, La Jolla Pharmaceutical Company, Oncodesign SA, Pfizer Inc, Regeneron Pharmaceuticals Inc. The report covers ... The ... Leggi

The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial - Benzinga

... Committees, and clinical investigators of the study to review the data and determine next steps for the AFM11 program. The shares fell 24.89 percent to $3.47 in after-hours trading. ... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) presented Phase 2 ... Leggi

Xconomy: Anaplan Ups Estimate For Its IPO Haul; Allogene IPO ... - Xconomy

San Francisco-based Anaplan, one of five companies planning to close initial public offerings this week, raised the expected price range for its shares in.altro » Leggi

Financial Comparison: La Jolla Pharmaceutical (LJPC) & Idera Pharmaceuticals (IDRA) - Marea Informative (blog)

La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Summary. Idera Pharmaceuticals beats La Jolla Pharmaceutical on 9 of the 12 factors ...altro » Leggi

Analyzing La Jolla Pharmaceutical (LJPC) & Idera Pharmaceuticals (NASDAQ:IDRA) - Baseball Daily News

Idera Pharmaceuticals has higher revenue and earnings than La Jolla Pharmaceutical. La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.altro » Leggi

Contrasting Tetraphase Pharmaceuticals (NASDAQ:TTPH) & Orexigen Therapeutics (OREX) - Baseball Daily News

Tetraphase Pharmaceuticals is trading at a lower price-to-earnings ratio than Orexigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Risk and Volatility. Orexigen Therapeutics has a beta of 2.46, meaning that its ...altro » Leggi

Tetraphase Pharmaceuticals (NASDAQ:TTPH) and Orexigen Therapeutics (OREX) Financial Survey - Marea Informative (blog)

Orexigen Therapeutics has higher revenue and earnings than Tetraphase Pharmaceuticals. Tetraphase Pharmaceuticals is trading at a lower price-to-earnings ratio than Orexigen Therapeutics, indicating that it is currently the more affordable of the two ...altro » Leggi